Lexapro SSRI Switch Plan On Target Despite Slower Than Expected Decline In Celexa Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest attributes the majority of Celexa’s $15.4 mil. sequential quarterly sales growth to a 4% price increase taken in March. Forest’s estimates put the Celexa revenue run rate in early 2005 at $680 mil., above earlier predictions.
You may also be interested in...
Cephalon's Nuvigil Will Be Discounted To Provigil, But Not "At A Low Price"
Cephalon will encourage patients to switch to follow-on Nuvigil by increasing the Provigil price "dramatically" ahead of generic competition. The company will file the Nuvigil NDA within the next couple of weeks.
Cephalon's Nuvigil Will Be Discounted To Provigil, But Not "At A Low Price"
Cephalon will encourage patients to switch to follow-on Nuvigil by increasing the Provigil price "dramatically" ahead of generic competition. The company will file the Nuvigil NDA within the next couple of weeks.
Forest Sees No Significant Impact From Antidepressant "Black Box" Warnings
The antidepressant relabeling will only have a "mild" effect on a small part of the business, Forest says. Some of the impact could be offset if competitors scale back on direct-to-consumer advertisements: Pfizer is still running Zoloft TV ads in the days following FDA's decision to require new warnings.